DexCom, Inc. (DXCM) Covered Calls

DexCom, Inc. is a medical device leader specializing in continuous glucose monitoring (CGM) systems for people with diabetes and those interested in metabolic health. Headquartered in San Diego, California, the company designs and commercializes wearable sensor technology that provides real-time glucose data, reducing the need for traditional fingersticks. Through its G-series and Stelo platforms, DexCom empowers users and clinicians with actionable insights to improve health outcomes.

You can sell covered calls on DexCom, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for DXCM (prices last updated Tue 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

DexCom, Inc. (DXCM) is a pioneer in the design and commercialization of high-performance continuous glucose monitoring (CGM) systems. The company’s primary focus is providing accurate, real-time glucose data to individuals with Type 1 and Type 2 diabetes. Its flagship product, the Dexcom G7, features a small, all-in-one wearable sensor and transmitter that sends glucose readings every five minutes to compatible smart devices. In late 2025 and early 2026, the company successfully transitioned its hardware portfolio to the G7 15-day system, significantly extending sensor wear-time and improving patient convenience while reducing long-term costs.

A critical strategic shift for the company occurred in 2024 and 2025 with the launch of Stelo, the first over-the-counter glucose biosensor cleared for use by adults with Type 2 diabetes who do not use insulin. By early 2026, DexCom has significantly expanded its addressable market by targeting the broader metabolic health and wellness category. This initiative is supported by the My Dexcom Account digital ecosystem and integrations with third-party wearables like the Apple Watch and Oura Ring. Furthermore, the company is scaling its international manufacturing footprint with a new high-capacity facility in Athenry, Ireland, which is designed to support growing global demand and drive gross margin expansion through automated production efficiencies.

Competitive Landscape

The competitive landscape for DexCom consists of diversified medical technology giants and specialized diabetes care firms. Primary rivals that are publicly traded on the NASDAQ or NYSE and offer highly active options markets include Abbott Laboratories and Medtronic plc. Abbott’s FreeStyle Libre system is the direct primary competitor to DexCom’s G-series and Stelo platforms in the global CGM market.

Other notable competitors in the diabetes technology and insulin delivery sectors with active options trading include Insulet Corporation and Tandem Diabetes Care, Inc.. DexCom distinguishes itself through its "best-in-class" accuracy and its open-architecture approach, which allows its sensors to integrate seamlessly with various automated insulin delivery (AID) systems from both Insulet and Tandem. While competitors often bundle hardware, DexCom’s "pure-play" sensor focus allows it to maintain a technological moat in biosensing accuracy and rapid software iteration, which is highly valued by the intensive insulin-using population.

Strategic Outlook

Strategic innovation is currently focused on the rollout of "Smart Basal" technology and the integration of Agentic AI within the Stelo app. By early 2026, the company has prioritized providing hyper-personalized metabolic coaching, using generative AI to analyze the relationship between nutrition, exercise, and glucose variability. This shift toward a "software-as-a-service" (SaaS) model is intended to diversify revenue streams and increase user retention by embedding the DexCom platform more deeply into daily lifestyle management.

The long-term outlook involves a disciplined expansion into non-diabetes clinical applications, including pre-diabetes, obesity management, and hospital-based glucose monitoring. Management is prioritizing the transition toward a more capital-efficient manufacturing model while pursuing broader reimbursement for non-insulin users in major European markets and Japan. By maintaining its lead in biosensor miniaturization—with a next-generation "G8" sensor currently in development that is 50% smaller than the G7—DexCom aims to solidify its position as the standard-of-care for real-time health monitoring in an era of data-driven personalized medicine.

Want more examples? DXC Covered Calls | DXD Covered Calls